Paushak Ltd. Share Price & Stock Analysis

Paushak Ltd. (BSE: 532742) is a Vadodara, Gujarat-based company in the Custom Synthesis and Specialty CDMO industry. With a market capitalisation of ₹1,487 Cr, it ranks #1,389 by market cap among the 6,197 Indian listed companies on FinBizNet, and #6 of 13 in Custom Synthesis and Specialty CDMO. At ₹600.00 (as of 16 Nov 2026), the share price is 32.0% below its 52-week high of ₹881.95 and 75.2% above its 52-week low of ₹342.50.

Key Metrics

Current Price₹600.00
Market Cap₹1,487 Cr
BSE Code532742
SectorMaterials > Chemicals > Speciality Chemicals
Sub-IndustrySpecialty Chemicals > Custom Synthesis and Specialty CDMO
P/E Ratio38.1
Return on Equity8.22%
Return on Assets4.01%
52-Week Range₹342.50 – ₹881.95
3-Month Price Change-19.7%
Beta (1Y)0.73
Dividend Yield0.41%
HeadquartersVadodara, Gujarat
Websitewww.paushak.com

Latest Quarterly Results — Q2 FY27

Revenue₹89 Cr
Net Profit₹14 Cr
Net Margin15.1%
EPS (Basic)₹5.48
Basisstandalone

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Paushak Ltd. Quarterly Revenue and Profit Trend

Paushak Ltd. reported revenue of ₹89 Cr in Q2 FY27, up 6.9% from ₹84 Cr in Q1 FY27. It posted a net profit of ₹14 Cr for the quarter, against a net profit of ₹15 Cr in Q1 FY27 (down 10.5%). Across the 4 quarters from Q3 FY26 to Q2 FY27, quarterly revenue ranged from ₹49 Cr (Q3 FY26) to ₹89 Cr (Q2 FY27). The company was profitable in each of these 4 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹89 Cr₹14 Cr15.1%
Q1 FY27₹84 Cr₹15 Cr18.1%
Q4 FY26₹55 Cr₹13 Cr22.7%
Q3 FY26₹49 Cr₹6 Cr12.6%

Standalone figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 67.28% of Paushak Ltd.'s shares as of Sept 2026, unchanged from Nov 2025. Delivery averaged 49.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Paushak Ltd.

Paushak Limited manufactures and sells specialty chemicals and intermediates in India and internationally. It offers chloroformates, isocyanates, chlorides, carbonate/carbamate, and custom synthesis and CDMO. The company servers its products to pharmaceuticals, agrochemicals, and performance and custom synthesis industries. Paushak Limited was founded in 1968 and is based in Vadodara, India.

Products and Services

1. Speciality Chemicals-This segment develops, manufactures, and sells phosgene based specialty chemicals and intermediates.

Business Segments

1. Speciality Chemicals-100%

Paushak Ltd. vs Peers — Custom Synthesis and Specialty CDMO

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Anupam Rasayan India Ltd₹13,570 Cr79.65.76%₹806 Cr+20.1%
Neogen Chemicals Limited (Neogen)₹8,322 Cr259.23.58%₹296 Cr+93.4%
Prasol Chemicals Limited₹4,681 Cr58.1—₹413 Cr—
Laxmi Organic Industries Ltd₹4,574 Cr57.24.08%₹1,083 Cr-18.9%
Tatva Chintan Pharma Chem Ltd₹3,871 Cr92.55.53%₹217 Cr+12.2%
Paushak Ltd.₹1,487 Cr38.18.22%₹89 Cr—
Sunshield Chemicals Ltd.₹833 Cr25.217.02%—+12.6%
Chemcon Speciality Chemicals Limited₹733 Cr31.84.80%₹65 Cr-12.8%
Resonance Specialties Ltd.₹327 Cr31.515.15%—+203.4%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Paushak Ltd.?

Paushak Ltd. is trading at ₹600.00, with a market capitalisation of ₹1,487 Cr.

Which sector does Paushak Ltd. belong to?

Paushak Ltd. operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Custom Synthesis and Specialty CDMO).

What are the key financial ratios of Paushak Ltd.?

Paushak Ltd. has a P/E of 38.1 and a return on equity of 8.22%.

What is the stock symbol of Paushak Ltd.?

Paushak Ltd. is listed on the BSE under the scrip code 532742.

What were Paushak Ltd.'s latest quarterly results?

In Q2 FY27, Paushak Ltd. reported revenue of ₹89 Cr and net profit of ₹14 Cr, with basic EPS of ₹5.48 (standalone, parsed from the company's exchange filing).

What is the promoter holding in Paushak Ltd.?

Promoters held 67.28% of Paushak Ltd.'s shares as of Sept 2026, unchanged from Nov 2025.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.